Handelsbanken Fonder AB Sells 39,718 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Handelsbanken Fonder AB decreased its position in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 4.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 891,918 shares of the biopharmaceutical company's stock after selling 39,718 shares during the quarter. Handelsbanken Fonder AB owned approximately 0.15% of Royalty Pharma worth $25,054,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Allworth Financial LP increased its position in Royalty Pharma by 89.8% during the third quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 451 shares during the period. Toroso Investments LLC increased its position in Royalty Pharma by 0.9% during the third quarter. Toroso Investments LLC now owns 57,102 shares of the biopharmaceutical company's stock worth $1,550,000 after acquiring an additional 504 shares during the period. EverSource Wealth Advisors LLC increased its position in Royalty Pharma by 112.0% during the third quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 531 shares during the period. PNC Financial Services Group Inc. increased its position in Royalty Pharma by 10.8% during the third quarter. PNC Financial Services Group Inc. now owns 5,509 shares of the biopharmaceutical company's stock worth $150,000 after acquiring an additional 536 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. increased its position in Royalty Pharma by 8.0% during the third quarter. Tokio Marine Asset Management Co. Ltd. now owns 8,210 shares of the biopharmaceutical company's stock worth $223,000 after acquiring an additional 607 shares during the period. Institutional investors own 54.35% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on RPRX shares. Bank of America decreased their price target on shares of Royalty Pharma from $40.00 to $38.00 and set a "buy" rating on the stock in a research note on Friday, April 12th. JPMorgan Chase & Co. decreased their price target on shares of Royalty Pharma from $45.00 to $42.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 20th. StockNews.com upgraded shares of Royalty Pharma from a "hold" rating to a "buy" rating in a research note on Thursday, April 11th. Finally, The Goldman Sachs Group decreased their price target on shares of Royalty Pharma from $56.00 to $50.00 and set a "buy" rating on the stock in a research note on Tuesday, February 20th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $46.75.

Royalty Pharma Stock Performance

Shares of NASDAQ:RPRX remained flat at $27.82 on Tuesday. 4,682,023 shares of the stock traded hands, compared to its average volume of 2,660,089. Royalty Pharma plc has a 52 week low of $25.92 and a 52 week high of $36.19. The company has a quick ratio of 7.90, a current ratio of 7.90 and a debt-to-equity ratio of 0.61. The company has a fifty day moving average of $29.72 and a 200 day moving average of $28.55. The company has a market cap of $16.62 billion, a P/E ratio of 14.72 and a beta of 0.45.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last issued its earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating the consensus estimate of $1.03 by $0.12. The company had revenue of $736.00 million for the quarter, compared to the consensus estimate of $702.90 million. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. As a group, sell-side analysts predict that Royalty Pharma plc will post 3.95 EPS for the current year.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 17th will be given a dividend of $0.21 per share. The ex-dividend date is Thursday, May 16th. This represents a $0.84 annualized dividend and a yield of 3.02%. Royalty Pharma's dividend payout ratio (DPR) is 44.44%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.